Cathie Wood's ARK ETFs made notable moves on Wednesday, March 27th, 2024, with significant trading activity observed across various sectors. The daily trade report revealed a mix of buys and sells, with the largest dollar-value buy being in TWIST BIOSCIENCE CORP (NASDAQ:TWST), where ARK purchased a total of 33,994 shares. This transaction, split between its ARKK and ARKG ETFs, amounted to $1,147,297. The purchase underscores ARK's continued interest in the biotech sector, particularly in companies specializing in synthetic biology and genomics.
The day's largest sell was in UIPATH INC (NYSE:PATH), with ARKQ ETF offloading a total of 71,688 shares, resulting in a sale value of $1,628,034. This move might indicate a strategic shift or a rebalancing of ARK's portfolio in the automation and artificial intelligence space.
Another significant buy was in 10X GENOMICS INC (NASDAQ:TXG), a genomics company, where ARK acquired a total of 32,209 shares across ARKK and ARKG ETFs. The total dollar value for this trade reached $1,167,576, reflecting ARK's bullish stance on the genomics industry.
In the defense sector, ARK bought a total of 53,935 shares of KRATOS DEFENSE & SECURITY (NASDAQ:KTOS), with purchases made through both ARKQ and ARKX ETFs, totaling a dollar value of $959,503. This trade follows a pattern of investment in Kratos, as ARK had also acquired shares of the company on the previous Tuesday and Monday, signaling a growing position in the defense technology provider.
Additionally, ARK invested in PERSONALIS INC (NASDAQ:PSNL), a cancer genomics company, buying 49,142 shares through its ARKG ETF, amounting to $70,273. This purchase is part of a trend, as ARK has been accumulating shares of Personalis (NASDAQ:PSNL) over the past week, indicating confidence in the company's trajectory.
The daily report also highlighted smaller buys, including 2,592 shares of ROBLOX CORP (NYSE:RBLX) and 657 shares of PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB), totaling $96,655 and $2,312 respectively. These trades, although modest in comparison to others, are part of ARK's diverse investment strategy across emerging technologies and entertainment platforms.
Investors following Cathie Wood's ARK ETFs will likely analyze these trades to gauge the fund's market outlook and strategic positioning. The continued investment in genomics and defense, coupled with the sell-off in automation technology, may offer insights into where ARK sees potential growth and risk in the current economic climate.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.